{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:10:10Z","timestamp":1790759410286,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Youth Science and Technology Project of Health Commission of Hebei Province","award":["Grant No. 20201056"],"award-info":[{"award-number":["Grant No. 20201056"]}]},{"name":"the Youth Science and Technology Project of Health Commission of Hebei Province","award":["Grant No. 20201056"],"award-info":[{"award-number":["Grant No. 20201056"]}]},{"name":"the Youth Science and Technology Project of Health Commission of Hebei Province","award":["Grant No. 20201056"],"award-info":[{"award-number":["Grant No. 20201056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing evidence has convincingly shown that abnormal pre-mRNA splicing is implicated in the development of most human malignancies. Serine\/arginine-rich protein kinase 1 (SRPK1), a key splicing regulator, is reported to be\u00a0overexpressed in leukemia and other cancer types, which suggests the therapeutic potential of targeting SRPK1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SRPK1 expression was measured in 41 ENKTL patients by immunohistochemistry and mRNA expression was analyzed by qRT\u2012PCR. We knocked down SRPK1 expression in\u00a0the ENKTL cell line YT by siRNA transfection\u00a0and inhibited SRPK1 using inhibitors (SPHINX31 and SRPIN340) in YT cells and peripheral blood lymphocytes (PBLs) isolated from ENKTL patients\u00a0to investigate its role in cell proliferation and apoptosis. Then, RNA-seq analysis was performed to predict the potential signaling pathway by which SRPK1 inhibition induces cell death and further verified this prediction by Western blotting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the present study, we initially evaluated the clinical significance of SRPK1 in extranodal natural killer\/T-cell lymphoma (ENKTL), a very aggressive subtype of non-Hodgkin lymphoma. The expression of SRPK1 in ENKLT patients was examined by immunohistochemistry and qRT\u2012PCR, which revealed SRPK1 overexpression in more than 60% of ENKTL specimens and its association with worse survival. Cellular experiments using the human ENKTL cell line YT and PBLs from ENKTL patients, demonstrated that inhibition of SRPK1 suppressed cell proliferation and induced apoptosis. Subsequently, we investigated the downstream targets of SRPK1 by RNA-seq analysis and found that SRPK1 inhibition induced ATF4\/CHOP pathway activation and AKT1 inhibition. Furthermore, ENKTL patients presenting high SRPK1 expression showed resistance to cisplatin-based chemotherapy. The association of SRPK1 expression with cisplatin resistance was also confirmed in YT cells. SRPK1 overexpression via pLVX-SRPK1 plasmid  transfection\u00a0dramatically decreased the sensitivity of YT cells to cisplatin, while siRNA-mediated\u00a0SRPK1 knockdown or SRPK1 inhibitor treatment  significantly increased cisplatin cytotoxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In summary, these results support that SRPK1 might be a useful clinical prognostic indicator and therapeutic target for ENKTL, especially for patients who\u00a0relapse after cisplatin-based chemotherapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10158-6","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:04:03Z","timestamp":1666857843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK\/T-cell lymphoma cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Cuiying","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-You","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"4","key":"10158_CR1","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3026(19)30283-2","volume":"7","author":"CP Fox","year":"2020","unstructured":"Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020;7(4):e284\u201394. https:\/\/doi.org\/10.1016\/S2352-3026(19)30283-2.","journal-title":"Lancet Haematol."},{"issue":"1","key":"10158_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","volume":"10","author":"E Tse","year":"2017","unstructured":"Tse E, Kwong YL. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. https:\/\/doi.org\/10.1186\/s13045-017-0452-9.","journal-title":"J Hematol Oncol."},{"issue":"7778","key":"10158_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","volume":"574","author":"D Inoue","year":"2019","unstructured":"Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D\u2019Avino AR, Hitchman T, North K, Lee SC, Bitner L, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574(7778):432\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1646-9.","journal-title":"Nature."},{"issue":"1","key":"10158_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","volume":"23","author":"M Seiler","year":"2018","unstructured":"Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep. 2018;23(1):282-296.e284. https:\/\/doi.org\/10.1016\/j.celrep.2018.01.088.","journal-title":"Cell Rep."},{"issue":"7780","key":"10158_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-019-1651-z","volume":"574","author":"S Shuai","year":"2019","unstructured":"Shuai S, Suzuki H, Diaz-Navarro A, Nadeu F, Kumar SA, Gutierrez-Fernandez A, Delgado J, Pinyol M, Lopez-Otin C, Puente XS, et al. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature. 2019;574(7780):712\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1651-z.","journal-title":"Nature."},{"issue":"7","key":"10158_CR6","first-page":"663","volume":"1","author":"XD Fu","year":"1995","unstructured":"Fu XD. The superfamily of arginine\/serine-rich splicing factors. RNA. 1995;1(7):663\u201380.","journal-title":"RNA."},{"issue":"11","key":"10158_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1101\/gad.1934910","volume":"24","author":"JL Manley","year":"2010","unstructured":"Manley JL, Krainer AR. A rational nomenclature for serine\/arginine-rich protein splicing factors (SR proteins). Genes Dev. 2010;24(11):1073\u20134. https:\/\/doi.org\/10.1101\/gad.1934910.","journal-title":"Genes Dev."},{"issue":"6482","key":"10158_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/369678a0","volume":"369","author":"JF Gui","year":"1994","unstructured":"Gui JF, Lane WS, Fu XD. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature. 1994;369(6482):678\u201382. https:\/\/doi.org\/10.1038\/369678a0.","journal-title":"Nature."},{"issue":"3","key":"10158_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00412-013-0407-z","volume":"122","author":"Z Zhou","year":"2013","unstructured":"Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma. 2013;122(3):191\u2013207. https:\/\/doi.org\/10.1007\/s00412-013-0407-z.","journal-title":"Chromosoma."},{"issue":"2","key":"10158_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1091\/mbc.e05-10-0963","volume":"17","author":"JH Ding","year":"2006","unstructured":"Ding JH, Zhong XY, Hagopian JC, Cruz MM, Ghosh G, Feramisco J, Adams JA, Fu XD. Regulated cellular partitioning of SR protein-specific kinases in mammalian cells. Mol Biol Cell. 2006;17(2):876\u201385. https:\/\/doi.org\/10.1091\/mbc.e05-10-0963.","journal-title":"Mol Biol Cell."},{"key":"10158_CR11","doi-asserted-by":"publisher","unstructured":"Nikas IP, Themistocleous SC, Paschou SA, Tsamis KI, Ryu HS. Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives. Cells. 2019;9 (1):\u00a0https:\/\/doi.org\/10.3390\/cells9010019","DOI":"10.3390\/cells9010019"},{"issue":"3","key":"10158_CR12","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1080\/21655979.2022.2034705","volume":"13","author":"Z Dong","year":"2022","unstructured":"Dong Z, Chang X, Xie L, Wang Y, Hou Y. Increased expression of SRPK1 (serine\/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma. Bioengineered. 2022;13(3):6100\u201312. https:\/\/doi.org\/10.1080\/21655979.2022.2034705.","journal-title":"Bioengineered."},{"issue":"4","key":"10158_CR13","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1172\/JCI74440","volume":"125","author":"W van Roosmalen","year":"2015","unstructured":"van Roosmalen W, Le Devedec SE, Golani O, Smid M, Pulyakhina I, Timmermans AM, Look MP, Zi D, Pont C, de Graauw M, et al. Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. J Clin Invest. 2015;125(4):1648\u201364. https:\/\/doi.org\/10.1172\/JCI74440.","journal-title":"J Clin Invest."},{"key":"10158_CR14","doi-asserted-by":"publisher","unstructured":"Yao Y, Li Q, Wang H. MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1. Onco Targets Ther. 2018;11(1671\u20131681. https:\/\/doi.org\/10.2147\/OTT.S161835","DOI":"10.2147\/OTT.S161835"},{"issue":"8","key":"10158_CR15","doi-asserted-by":"publisher","first-page":"13582","DOI":"10.1002\/jcp.28036","volume":"234","author":"Y Li","year":"2019","unstructured":"Li Y, Yu S, Wang X, Ye X, He B, Quan M, Gao Y. SRPK1 facilitates tumor cell growth via modulating the small nucleolar RNA expression in gastric cancer. J Cell Physiol. 2019;234(8):13582\u201391. https:\/\/doi.org\/10.1002\/jcp.28036.","journal-title":"J Cell Physiol."},{"key":"10158_CR16","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2015_051","author":"F Wang","year":"2015","unstructured":"Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, Guo H, Yu C. Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma. 2015. https:\/\/doi.org\/10.4149\/neo_2015_051.","journal-title":"Neoplasma"},{"issue":"11","key":"10158_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/2159-8290.CD-19-0399","volume":"9","author":"EA Obeng","year":"2019","unstructured":"Obeng EA, Stewart C, Abdel-Wahab O. Altered RNA Processing in Cancer Pathogenesis and Therapy. Cancer Discov. 2019;9(11):1493\u2013510. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0399.","journal-title":"Cancer Discov."},{"issue":"3","key":"10158_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1365-2141.2005.05619.x","volume":"130","author":"M Hishizawa","year":"2005","unstructured":"Hishizawa M, Imada K, Sakai T, Ueda M, Hori T, Uchiyama T. Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol. 2005;130(3):382\u201390. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05619.x.","journal-title":"Br J Haematol."},{"issue":"1","key":"10158_CR19","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-018-07620-0","volume":"9","author":"K Tzelepis","year":"2018","unstructured":"Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, et al. SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nat Commun. 2018;9(1):5378. https:\/\/doi.org\/10.1038\/s41467-018-07620-0.","journal-title":"Nat Commun."},{"issue":"4","key":"10158_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 2016;17(4):1193\u2013205. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.079.","journal-title":"Cell Rep."},{"issue":"20","key":"10158_CR21","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood."},{"issue":"19","key":"10158_CR22","first-page":"6982","volume":"61","author":"PW Schenk","year":"2001","unstructured":"Schenk PW, Boersma AW, Brandsma JA, den Dulk H, Burger H, Stoter G, Brouwer J, Nooter K. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res. 2001;61(19):6982\u20136.","journal-title":"Cancer Res."},{"issue":"4","key":"10158_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1593\/neo.03406","volume":"6","author":"PW Schenk","year":"2004","unstructured":"Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH, Nooter K. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia. 2004;6(4):297\u2013301. https:\/\/doi.org\/10.1593\/neo.03406.","journal-title":"Neoplasia."},{"issue":"7","key":"10158_CR24","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1158\/0008-5472.CAN-05-4065","volume":"66","author":"GM Hayes","year":"2006","unstructured":"Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006;66(7):3819\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4065.","journal-title":"Cancer Res."},{"issue":"5","key":"10158_CR25","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/0008-5472.Can-06-2969","volume":"67","author":"GM Hayes","year":"2007","unstructured":"Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007;67(5):2072\u201380. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-2969.","journal-title":"Cancer Res."},{"issue":"7","key":"10158_CR26","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1007\/s13277-015-4738-7","volume":"37","author":"I Sigala","year":"2016","unstructured":"Sigala I, Tsamis KI, Gousia A, Alexiou G, Voulgaris S, Giannakouros T, Kyritsis AP, Nikolakaki E. Expression of SRPK1 in gliomas and its role in glioma cell lines viability. Tumour Biol. 2016;37(7):8699\u2013707. https:\/\/doi.org\/10.1007\/s13277-015-4738-7.","journal-title":"Tumour Biol."},{"issue":"4","key":"10158_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.leu.2403310","volume":"18","author":"S Salesse","year":"2004","unstructured":"Salesse S, Dylla SJ, Verfaillie CM. p210BCR\/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia. 2004;18(4):727\u201333. https:\/\/doi.org\/10.1038\/sj.leu.2403310.","journal-title":"Leukemia."},{"issue":"1","key":"10158_CR28","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3892\/mmr.2017.8032","volume":"17","author":"H Wang","year":"2018","unstructured":"Wang H, Ge W, Jiang W, Li D, Ju X. SRPK1siRNA suppresses K562 cell growth and induces apoptosis via the PARPcaspase3 pathway. Mol Med Rep. 2018;17(1):2070\u20136. https:\/\/doi.org\/10.3892\/mmr.2017.8032.","journal-title":"Mol Med Rep."},{"key":"10158_CR29","doi-asserted-by":"publisher","unstructured":"Siqueira RP, Caetano MMM, de Souza LA, Dos Passos PMS, Simaroli NB, Barros MVA, de Souza APM, de Oliveira LL, Silva-Junior A, Fietto JLR et al. Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells. Toxicol In Vitro. 2020;65 (104777. https:\/\/doi.org\/10.1016\/j.tiv.2020.104777","DOI":"10.1016\/j.tiv.2020.104777"},{"issue":"1","key":"10158_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s42003-020-0983-4","volume":"3","author":"C Wang","year":"2020","unstructured":"Wang C, Zhou Z, Subhramanyam CS, Cao Q, Heng ZSL, Liu W, Fu X, Hu Q. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells. Commun Biol. 2020;3(1):268. https:\/\/doi.org\/10.1038\/s42003-020-0983-4.","journal-title":"Commun Biol."},{"issue":"4","key":"10158_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/path.4846","volume":"241","author":"N Bullock","year":"2017","unstructured":"Bullock N, Oltean S. The many faces of SRPK1. J Pathol. 2017;241(4):437\u201340. https:\/\/doi.org\/10.1002\/path.4846.","journal-title":"J Pathol."},{"issue":"2","key":"10158_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41401-020-0466-7","volume":"42","author":"XX Yu","year":"2021","unstructured":"Yu XX, Zhu MY, Wang JR, Li H, Hu P, Qing YJ, Wang XY, Wang HZ, Wang ZY, Xu JY, et al. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2alpha-ATF4-CHOP axis. Acta Pharmacol Sin. 2021;42(2):290\u2013300. https:\/\/doi.org\/10.1038\/s41401-020-0466-7.","journal-title":"Acta Pharmacol Sin."},{"key":"10158_CR33","doi-asserted-by":"publisher","unstructured":"Liu H, Xiong C, Liu J, Sun T, Ren Z, Li Y, Geng J, Li X. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4\/CHOP pathway in multiple myeloma. Biomed Pharmacother. 2020;125(110005. https:\/\/doi.org\/10.1016\/j.biopha.2020.110005","DOI":"10.1016\/j.biopha.2020.110005"},{"issue":"9","key":"10158_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s1875-5364(18)30109-2","volume":"16","author":"W Peng","year":"2018","unstructured":"Peng W, Chen BA. Gambogic acid induces cell apoptosis through endoplasmic reticulum stress triggered inhibition of Akt signaling pathways in extranodal NK\/T-cell lymphoma cells. Chin J Nat Med. 2018;16(9):693\u20139. https:\/\/doi.org\/10.1016\/s1875-5364(18)30109-2.","journal-title":"Chin J Nat Med."},{"issue":"4","key":"10158_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.16435","volume":"189","author":"D Huang","year":"2020","unstructured":"Huang D, Song TL, Nairismagi ML, Laurensia Y, Pang WL, Zhe DCM, Wong EKY, Wijaya GG, Tan J, Tan SH, et al. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma. Br J Haematol. 2020;189(4):731\u201344. https:\/\/doi.org\/10.1111\/bjh.16435.","journal-title":"Br J Haematol."},{"key":"10158_CR36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2741\/1592","volume":"10","author":"D Kim","year":"2005","unstructured":"Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, et al. AKT\/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005;10:975\u201387. https:\/\/doi.org\/10.2741\/1592.","journal-title":"Front Biosci."},{"issue":"16","key":"10158_CR37","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","volume":"23","author":"Y Pommier","year":"2004","unstructured":"Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934\u201349. https:\/\/doi.org\/10.1038\/sj.onc.1207515.","journal-title":"Oncogene."},{"issue":"3","key":"10158_CR38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/0008-5472.Can-10-1481","volume":"71","author":"T Sen","year":"2011","unstructured":"Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, Ratovitski E, Sidransky D. DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res. 2011;71(3):1167\u201376. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-1481.","journal-title":"Cancer Res."},{"issue":"2","key":"10158_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3892\/or.2017.6109","volume":"39","author":"C Tang","year":"2018","unstructured":"Tang C, Luo H, Luo D, Yang H, Zhou X. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras\/PI3K\/Akt1\/survivin pathway in lung cancer cells. Oncol Rep. 2018;39(2):611\u20138. https:\/\/doi.org\/10.3892\/or.2017.6109.","journal-title":"Oncol Rep."},{"issue":"1","key":"10158_CR40","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ptr.6798","volume":"35","author":"L Zhao","year":"2021","unstructured":"Zhao L, Zhang W, Zhang F. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells. Phytother Res. 2021;35(1):278\u201388. https:\/\/doi.org\/10.1002\/ptr.6798.","journal-title":"Phytother Res."},{"issue":"4","key":"10158_CR41","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3892\/or.2020.7710","volume":"44","author":"N Dukaew","year":"2020","unstructured":"Dukaew N, Chairatvit K, Pitchakarn P, Imsumran A, Karinchai J, Tuntiwechapikul W, Wongnoppavich A. Inactivation of AKT\/NFkappaB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin. Oncol Rep. 2020;44(4):1441\u201354. https:\/\/doi.org\/10.3892\/or.2020.7710.","journal-title":"Oncol Rep."},{"issue":"10","key":"10158_CR42","doi-asserted-by":"publisher","first-page":"e22560","DOI":"10.1002\/jbt.22560","volume":"34","author":"S Zhang","year":"2020","unstructured":"Zhang S, Wang Y. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function. J Biochem Mol Toxicol. 2020;34(10):e22560. https:\/\/doi.org\/10.1002\/jbt.22560.","journal-title":"J Biochem Mol Toxicol."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10158-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10158-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10158-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:05:36Z","timestamp":1666857936000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10158-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10158"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10158-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants complied with the Declaration of Helsinki and were reviewed and approved by the Ethics Committee of the Forth Hospital of Hebei Medical University. The patients were informed that the resected specimens would be stored by the hospital and potentially used for scientific research, and that their privacy would be maintained. The Ethic Committee of the Forth Hospital of Hebei Medical University approved that waived the informed consent in this study. The patients who provided peripheral blood samples provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1100"}}